Protocol No.: R5678-ONC-1879

A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with or without Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated with PSMA Expression
Principal Investigator
Kolodney, Joanna
Phase
I/II (Cancer Control)
Age Group
Adult
Applicable Disease Site
Genitourinary Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Nina Moore, RN
Research Specialist
Phone: +1 304-293-2991

View on ClinicalTrials.gov